Medicine and Dentistry
Quality of Life
100%
Health
92%
Combination Therapy
53%
Therapeutic Procedure
53%
Patient
30%
Diseases
15%
Kidney Metastasis
15%
Clinical Trial
15%
Placebo
15%
Interferon
7%
Exercise
7%
Adverse Event
7%
Clear Cell Renal Cell Carcinoma
7%
Patient-Reported Outcome
7%
Bevacizumab
7%
Chemotherapeutic Agent
7%
Sorafenib
7%
Sunitinib
7%
Drug
7%
Everolimus
7%
Temsirolimus
7%
Molecularly Targeted Therapy
7%
Pazopanib
7%
Cytokine Therapy
7%
Inpatient
7%
Targeted Therapy
7%
Survival
7%
INIS
quality of life
100%
therapy
76%
patients
46%
kidneys
23%
carcinomas
23%
data
15%
diseases
15%
metastases
15%
levels
7%
drugs
7%
clinical trials
7%
comparative evaluations
7%
cytokines
7%
investigations
7%
interferon
7%
stabilization
7%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
15%
Kidney Metastasis
15%
Interferon
7%
Adverse Event
7%
Prognosis
7%
Bevacizumab
7%
Sunitinib
7%
Sorafenib
7%
Temsirolimus
7%
Everolimus
7%
Pazopanib
7%
Drug
7%
Survival
7%